专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006061216A2 GENETIC ALTERATIONS USEFUL FOR THE RESPONSE PREDICTION OF MALIGNANT NEOPLASIA TO TAXANE-BASED MEDICAL TREATMENTS 审中-公开
标题翻译：遗传改变有利于恶性黑质对基于TAXANE的医疗治疗的反应预测
公开(公告)号：WO2006061216A2
公开(公告)日：2006-06-15
申请号：PCT/EP2005/013141
申请日：2005-12-08
申请人： BAYER HEALTHCARE AG , STROPP, Udo , MUNNES, Marc , WIRTZ, Ralph, M.
发明人： STROPP, Udo , MUNNES, Marc , WIRTZ, Ralph, M.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/16
摘要： The invention provides novel compositions, methods and uses, for the diagnosis, prognosis, prediction, prevention and aid in treatment of malignant neoplasia such as breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer. Genes that are chromosomally amplified in breast tissue of breast cancer patients are disclosed. Further disclosed are chromosomally amplified genes and non-amplified genes that correlate to Taxane resistance, Taxane benefit or adverse Taxane reaction, which can be used as an aid to make therapy dicisions.
摘要翻译：本发明提供了用于诊断，预后，预测，预防和辅助治疗恶性肿瘤如乳腺癌，卵巢癌，胃癌，结肠癌，食管癌，间充质癌，膀胱癌或非癌症的新型组合物，方法和用途。 - 小细胞肺癌。公开了在乳腺癌患者的乳腺组织中染色体扩增的基因。进一步公开的是染色体扩增的基因和与紫杉烷抗性，紫杉烷受益或不利的紫杉烷反应相关的非扩增基因，其可以用作帮助进行治疗分割。

2. 发明申请

WO2003057911A3 SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTING CARDIOVASCULAR DISEASE AND MEDICATION EFFICACY 审中-公开
公开(公告)号：WO2003057911A3
公开(公告)日：2003-07-17
申请号：PCT/EP2003/000060
申请日：2003-01-07
申请人： BAYER HEALTHCARE AG , STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
发明人： STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
IPC分类号： C12N15/12
摘要： The present invention relates to isolated polynucleotides encoding a cardiovascular associated (CA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease, the polynucleotide is selected from the group comprising:SEQ ID 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for CA gene polypeptide and with or without the CA gene promoter sequence.The invention also provides diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. The invention provides further polymorphic sequences and other genes.

3. 发明申请

WO2007071382A2 METHOD FOR THE PREDICTION OF ADVERSE DRUG RESPONSES 审中-公开
标题翻译：预防药物不良反应的方法
公开(公告)号：WO2007071382A2
公开(公告)日：2007-06-28
申请号：PCT/EP2006/012265
申请日：2006-12-19
申请人： BAYER HEALTHCARE AG , SCHWERS, Stephan , STROPP, Udo , KALLABIS, Harald , SCHUPPERT, Andreas , BURGHAUS, Rolf , VON TÖRNE, Christian , SCHMITZ, Gerd
发明人： SCHWERS, Stephan , STROPP, Udo , KALLABIS, Harald , SCHUPPERT, Andreas , BURGHAUS, Rolf , VON TÖRNE, Christian , SCHMITZ, Gerd
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q1/42 , C12Q1/50 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172 , G01N33/92
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a SADR gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat statin induced adverse drug reactions (SADR), the polynucleotide is selected from the group comprising: SEQ ID 1-35 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for SADR gene polypeptide and with or without the SADR gene promoter sequence.
摘要翻译：本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否存在药物反应不利的风险的抗体。本发明还提供了多态序列和其他基因。本发明还涉及编码SADR基因多肽的分离的多核苷酸，其用于鉴定治疗剂并可用于制备治疗他汀类药物诱导的不良药物反应（SADR）的药物的方法中，所述多核苷酸选自SEQ ID No.1 -35具有等位基因变异，如包含在功能性周围的序列部分中所示，如SADR基因多肽的全长cDNA并具有或不具有SADR基因启动子序列。

4. 发明申请

WO2004067774A2 SINGLE NUCLEOTIDE POLYMORPHISMS AS PREDICTIVE DIAGNOSTICS FOR ADVERSE DRUG REACTIONS (ADR) AND DRUG EFFICACY 审中-公开
标题翻译：单核苷酸多态性作为不良药物反应（ADR）和药物效力的预测诊断
公开(公告)号：WO2004067774A2
公开(公告)日：2004-08-12
申请号：PCT/EP2004/000539
申请日：2004-01-23
申请人： BAYER HEALTHCARE AG , STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
发明人： STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
IPC分类号： C12Q1/68
CPC分类号： G01N33/5091 , C12Q1/6883 , C12Q2600/156 , G01N33/5008 , G01N33/502 , G01N33/6893 , G01N2800/52
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.
摘要翻译：本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否有患上药物反应风险的抗体或人类受试者是高反应者还是低反应者他汀类药物或代谢物。本发明提供了进一步的诊断方法和试剂盒，包括确定人受试者是否处于心血管疾病风险的抗体。本发明还提供了多态序列和其他基因。

5. 发明申请

WO2004018708A2 GENETIC POLYMORPHISMS SENSITIVELY PREDICTING ADVERSE DRUG REACTIONS (ADR) AND DRUG EFFICACY 审中-公开
标题翻译：遗传多态性对预后不良反应（ADR）和药物有效性的敏感性预测
公开(公告)号：WO2004018708A2
公开(公告)日：2004-03-04
申请号：PCT/EP2003/008298
申请日：2003-07-28
申请人： BAYER HEALTHCARE AG , SCHWERS, Stephan , KALLABIS, Harald , REIFENBERGER, Elke , STROPP, Udo , SCHMITZ, Gerd
发明人： SCHWERS, Stephan , KALLABIS, Harald , REIFENBERGER, Elke , STROPP, Udo , SCHMITZ, Gerd
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-21 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.
摘要翻译：本发明提供了诊断方法和试剂盒，包括寡核苷酸和/或多核苷酸或衍生物，还包括确定人受试者在他汀类药物治疗后是否有风险发生药物不良反应的抗体，或者人受试者是否他汀类药物的高或低反应者或良好或不好的代谢者。本发明提供了进一步的诊断方法和试剂盒，其包括确定人受试者是否有心血管疾病风险的抗体。本发明还提供了多态性序列和其他基因。本发明进一步涉及编码表型相关（PA）基因多肽的分离的多核苷酸，其用于鉴定治疗剂并用于制备治疗心血管疾病或影响药物应答的药物的方法，所述多核苷酸选自包含具有等位基因变异的SEQ ID1-121，所述等位基因变异包含在功能性包含的序列部分中，如PA基因多肽的全长cDNA和有或没有PA基因启动子序列。

6. 发明申请

WO2004069867A2 GENETIC POLYMORPHISMS AS PREDICTIVE DIAGNOSTICS FOR ADVERSE DRUG REACTIONS (ADR) AND DRUG EFFICACY 审中-公开
标题翻译：作为不良反应（ADR）和药物效力的预测诊断的遗传多态性
公开(公告)号：WO2004069867A2
公开(公告)日：2004-08-19
申请号：PCT/EP2004/000884
申请日：2004-01-31
申请人： BAYER HEALTHCARE AG , STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald , SCHMITZ, Gerd
发明人： STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald , SCHMITZ, Gerd
IPC分类号： C07K14/47
CPC分类号： C07K14/4702 , A61K38/00 , C07K14/7156 , C07K14/8132 , C12Q1/6876 , C12Q2600/156
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.
摘要翻译：本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括以及抗体，其确定人受试者在他汀类药物治疗后是否有获得药物不良反应的风险，或人类受试者是高反应者还是低反应者他汀类药物的代谢者或不良代谢。本发明提供了进一步的诊断方法和试剂盒，包括确定人类受试者是否处于心血管疾病风险的抗体。本发明还提供了多态序列和其他基因。

7. 发明申请

WO2003072813A3 SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTING ADVERSE DRUG REACTIONS AND MEDICATION EFFICACY 审中-公开
公开(公告)号：WO2003072813A3
公开(公告)日：2003-09-04
申请号：PCT/EP2003/001514
申请日：2003-02-14
申请人： BAYER HEALTHCARE AG , STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
发明人： STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
IPC分类号： C12N15/63
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising:SEQ ID 1-80 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.

8. 发明申请

WO2003059946A3 GENETIC POLYMORPHISMS PREDICTING CARDIOVASCULAR DISEASE AND MEDICATION EFFICACY 审中-公开
公开(公告)号：WO2003059946A3
公开(公告)日：2003-07-24
申请号：PCT/EP2003/000161
申请日：2003-01-10
申请人： BAYER HEALTHCARE AG , STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald , SCHMITZ, Gerd
发明人： STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald , SCHMITZ, Gerd
IPC分类号： C07K14/47
摘要： The present invention relates to isolated polynucleotides encoding a cardiovascular associated (CA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease, the polynucleotide is selected from the group comprising:SEQ ID 1, 2, 3, 4, 5, 6 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for CA gene polypeptide and with or without the CA gene promoter sequence.The invention also provides diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. The invention provides further polymorphic sequences and other genes.

9. 发明申请

WO2006008045A1 SINGLE NUCLEOTIDE POLYMORPHISMS AS PROGNOSTIC TOOL TO DIAGNOSE ADVERSE DRUG REACTIONS (ADR) AND DRUG EFFICACY 审中-公开
标题翻译：单核苷酸多态性作为诊断工具诊断不良药物反应（ADR）和药物效力
公开(公告)号：WO2006008045A1
公开(公告)日：2006-01-26
申请号：PCT/EP2005/007600
申请日：2005-07-13
申请人： BAYER HEALTHCARE AG , STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
发明人： STROPP, Udo , SCHWERS, Stephan , KALLABIS, Harald
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-131 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence. Sequences: The sequence section contains all phenotype associated (‘PA’) SNPs and adjacent genomic sequences. The position of the polymorphisms that were used for the association studies (‘baySNP’) is indicated. Sometimes additional variations are found in the surrounding genomic sequence, that are marked by it’s respective IUPAC code. Although those surrounding SNPs were not explicitly analyzed, they likely exihibit a similar association to a phenotype as the baySNP (due to linkage disequillibrium, Reich D.E. et al. Nature 411, 199-204, 2001).
摘要翻译：本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否有患上药物反应风险的抗体或人类受试者是高反应者还是低反应者他汀类药物或代谢物。本发明提供了进一步的诊断方法和试剂盒，包括确定人受试者是否处于心血管疾病风险的抗体。本发明还提供了多态序列和其他基因。本发明还涉及编码可用于鉴定治疗剂并用于制备治疗心血管疾病或影响药物应答的药物的方法中的表型相关（PA）基因多肽的分离的多核苷酸，所述多核苷酸选自SEQ ID NO： ID 1-131，其具有等位基因变异，如包含在功能性周围的序列部分中所示，如PA基因多肽的全长cDNA并具有或不具有PA基因启动子序列。序列：序列部分包含所有表型相关（'PA'）SNP和相邻基因组序列。指出用于关联研究（'baySNP'）的多态性的位置。有时在周围的基因组序列中会发现额外的变化，它们由相应的IUPAC代码标记。尽管周围的SNP没有被明确分析，但它们可能与baySNP（由于连锁不平衡，Reich D.E.等，Nature 411,199-204,2001）具有类似的表型关联。

10. 发明申请

WO2011121028A1 ALGORITHM FOR PREDICTION OF BENEFIT FROM ADDITION OF TAXANE TO STANDARD CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER 审中-公开
标题翻译：将TAXANE增加益处的优点与乳腺癌患者标准化疗相关的算法
公开(公告)号：WO2011121028A1
公开(公告)日：2011-10-06
申请号：PCT/EP2011/054915
申请日：2011-03-30
申请人： SIEMENS HEALTHCARE DIAGNOSTICS INC. , FOUNTZILAS, George , GEHRMANN, Mathias , KRONENWETT, Ralf , STROPP, Udo , WEBER, Karsten , WIRTZ, Ralph
发明人： FOUNTZILAS, George , GEHRMANN, Mathias , KRONENWETT, Ralf , STROPP, Udo , WEBER, Karsten , WIRTZ, Ralph
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , G06F19/20 , G06F19/24
摘要： The invention relates to a method or predicting an outcome of cancer in a patient suffering from cancer, said method comprising : (a) determining in a biological sample from said patient the expression level of at least one marker gene selected from AKR1C3, MAP4, SPP1, CXCL9, PTGER3, and VEGFC; (b) comparing said expression level to a reference pattern of expression, wherein an increased expression of said at least one marker gene is indicative of said patient having a benefit from microtubule stabilizing agent-based cytotoxic chemotherapy.
摘要翻译：本发明涉及一种方法或预测患有癌症的患者的癌症结果，所述方法包括：（a）在来自所述患者的生物样品中测定至少一种选自AKR1C3，MAP4，SPP1的标志物基因的表达水平，CXCL9，PTGER3和VEGFC; （b）将所述表达水平与表达的参考模式进行比较，其中所述至少一种标记基因的增加的表达指示所述患者具有基于微管稳定剂的细胞毒性化学疗法的益处。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式